Standard Contracts
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENTExclusive License and Research Collaboration Agreement • May 26th, 2004 • Metabasis Therapeutics Inc • Pharmaceutical preparations
This Agreement (this "Agreement") is dated as of December 23, 2003 (the "Effective Date"), and is entered into by and between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey ("Merck"), and METABASIS THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware ("Metabasis").
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between Artiva Biotherapeutics, Inc. and Merck Sharp & Dohme Corp.Exclusive License and Research Collaboration Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License and Research Collaboration Agreement (this “Agreement”) is effective as of January 27, 2021 (the “Effective Date”) and is entered into by and between Artiva Biotherapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Company”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”).
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT between IDENIX PHARMACEUTICALS, INC. and METABASIS THERAPEUTICS, INC.Exclusive License and Research Collaboration Agreement • March 13th, 2007 • Metabasis Therapeutics Inc • Pharmaceutical preparations • New York
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between COCRYSTAL PHARMA, INC. and MERCK SHARP & DOHME CORP.Exclusive License and Research Collaboration Agreement • April 1st, 2019 • Cocrystal Pharma, Inc. • Pharmaceutical preparations • New York
This Agreement (this “Agreement”) is effective as of January 2, 2019 (the “Effective Date”), and is entered into by and between Cocrystal Pharma, Inc., a corporation organized and existing under the laws of Delaware (“Cocrystal”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”).
ANDExclusive License and Research Collaboration Agreement • March 6th, 2007 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Re: Exclusive License and Research Collaboration Agreement dated as of December 23, 2003, as amended prior to the date hereof (as so amended, the “Collaboration Agreement”) between Merck & Co., Inc. (“Merck”) and Metabasis Therapeutics, Inc. (“Metabasis”)Exclusive License and Research Collaboration Agreement • March 23rd, 2006 • Metabasis Therapeutics Inc • Pharmaceutical preparations
This Letter (this “Letter”) will confirm the understanding of Merck and Metabasis regarding certain matters relating to the Collaboration Agreement and is intended to be legally binding on both parties. Capitalized terms used but not otherwise defined in this Letter shall have the meanings provided in the Collaboration Agreement. Pursuant to this Letter the Parties hereby agree to amend the Agreement as follows:
Re: Exclusive License and Research Collaboration Agreement dated as of December 23, 2003 (the “Collaboration Agreement”) between Merck & Co., Inc. (“Merck”) and Metabasis Therapeutics, Inc. (“Metabasis”)Exclusive License and Research Collaboration Agreement • May 16th, 2005 • Metabasis Therapeutics Inc • Pharmaceutical preparations
This Letter (this “Letter”) will confirm the understanding of Merck and Metabasis regarding certain matters relating to the Collaboration Agreement and is intended to be legally binding on both parties. Capitalized terms used but not otherwise defined in this Letter shall have the meanings provided in the Collaboration Agreement. The Parties hereby confirm, acknowledge and agree that (a) pursuant to Section 2.7.1 of the Collaboration Agreement, the Research Program Term has been extended by Merck, with Metabasis’ concurrence, for an additional one (1) year period beyond the Initial Research Program Term; and (b) without limiting any other provision of the Collaboration Agreement, such Extended Research Program Term shall remain subject to Section 2.7.2.
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between YUMANITY THERAPEUTICS INC. and MERCK SHARP & DOHME CORP.Exclusive License and Research Collaboration Agreement • October 28th, 2020 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • New York
This Agreement (this “Agreement”) is effective as of June 19, 2020, (the “Effective Date”) and is entered into by and between YUMANITY THERAPEUTICS INC., a corporation organized and existing under the laws of Delaware (“Company”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”).
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between MERCK & CO., INC. and SURMODICS, INC.Exclusive License and Research Collaboration Agreement • August 9th, 2007 • Surmodics Inc • Patent owners & lessors • New York
* Portions omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.
Re: Exclusive License and Research Collaboration Agreement dated as of December 23, 2003, as amended from time to time prior to the date hereof (as so amended, the ”Collaboration Agreement”) between Merck & Co., Inc. (“Merck”) and Metabasis...Exclusive License and Research Collaboration Agreement • August 11th, 2006 • Metabasis Therapeutics Inc • Pharmaceutical preparations
This Letter (this “Letter”) will confirm the understanding of Merck and Metabasis regarding certain matters relating to the Collaboration Agreement and is intended to be legally binding on both parties. Capitalized terms used but not otherwise defined in this Letter shall have the meanings provided in the Collaboration Agreement. Whereas the Research Program Term under the Collaboration Agreement was scheduled to have terminated on December 23, 2005 and the Parties have extended the Research Program Term under the terms and conditions specified in this Letter.
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between MERCK & CO., INC. and AVALON PHARMACEUTICALS, INC.Exclusive License and Research Collaboration Agreement • May 14th, 2007 • Avalon Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Agreement (this “Agreement”) is effective as of March 5, 2007 (the “Effective Date”), and is entered into by and between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey (“Merck”), and AVALON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“Avalon”).
Re: Exclusive License and Research Collaboration Agreement dated as of December 23, 2003, as amended prior to the date hereof (as so amended. the “Collaboration Agreement”) between Merck & Co., Inc. (“Merck”) and Metabasis Therapeutics, Inc. (“Metabasis”)Exclusive License and Research Collaboration Agreement • March 23rd, 2006 • Metabasis Therapeutics Inc • Pharmaceutical preparations
This Letter (this “Letter”) will confirm the understanding of Merck and Metabasis regarding certain matters relating to the Collaboration Agreement and is intended to be legally binding on both parties. Capitalized terms used but not otherwise defined in this Letter shall have the meanings provided in the Collaboration Agreement. Pursuant to this Letter the Parties hereby agree to amend the Agreement as follows:
Amendment No. 1 to Exclusive License and Research Collaboration Agreement by and between Merck Sharp & Dohme Corp.and Idera Pharmaceuticals, Inc.Exclusive License and Research Collaboration Agreement • August 12th, 2014 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment (“Amendment No. 1”) effective as of date or last signature (“Amendment No. 1 Effective Date”) confirms the mutual understanding between Merck Sharp & Dohme Corp. (“Merck”), and Idera Pharmaceuticals, Inc. (“Idera”) to amend certain terms and conditions of the Exclusive License and Research Collaboration Agreement between the Parties dated December 8, 2006, as modified by those certain letter agreements dated November 3, 2008, November 13, 2009, December 8, 2011, January 3, 2012, and January 6, 2012 (collectively, the “Agreement”).
